Protein-sparing effect in skeletal muscle of growth hormone treatment in critically ill patients.

What Was Tested

The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), published as a randomized controlled trial.

To investigate the effect of growth hormone (GH) treatment on skeletal muscle protein catabolism in patients with multiple organ failure in the intensive care unit (ICU).

Why It Was Studied

Skeletal muscle depletion affects the incidence of complications and the length of hospital stay.

A protein-sparing effect of GH treatment in skeletal muscle of long-term ICU patients was hypothesized.

Who Took Part

PubMed indexes the participants as adults, middle-aged adults, older adults and people over 80, both men and women.

How the Study Was Run

The researchers set it up as a randomized study.

The participants were allocated by chance, so the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group and the comparison group should start out alike.

Protein content, protein synthesis, water, nucleic acids, and free amino acids in muscle were analyzed.

What Was Measured

Topics PubMed links to this paper include APACHE, Amino Acids, Critical Illness, Glutamine, Growth Hormone, Multiple Organ Failure and Muscle, Skeletal.

What This Means in Plain Language

The paper is a randomized study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Results are reported in around 5 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2000 (Annals of surgery), a journal based in United States.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.